| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Macrolide
Tylvalosin tartrate targets bacterial ribosomes, binding to the 23S rRNA of the 50S ribosomal subunit. This binding inhibits protein synthesis, resulting in bacteriostatic activity against susceptible bacteria. The compound also exhibits antiviral activity against PRRSV and induces apoptosis. Its anti-inflammatory activity is mediated through inhibition of NF-κB activation. |
|---|---|
| ln Vitro |
Tylvalosin tartrate demonstrates in vitro antibacterial activity against Gram-positive bacteria and Mycoplasmas. It exhibits antiviral activity against PRRSV infection. The compound induces apoptosis in vitro and has anti-inflammatory activity by inhibiting NF-κB activation. These activities make it valuable for veterinary and antiviral research.
|
| ln Vivo |
In vivo activity of tylosin tartrate has been demonstrated in veterinary applications for treating chronic respiratory disease, infectious rhinitis, and airsacculitis in animals. It is used as an aid in the prevention and treatment of Swine Enzootic Pneumonia caused by Mycoplasma. Its anti-inflammatory and antiviral activities suggest additional therapeutic benefits.
|
| Enzyme Assay |
In vitro enzyme assays for tylosin tartrate include measuring its inhibition of NF-κB activation. Antibacterial activity is assessed using standard bacterial growth inhibition assays against Gram-positive bacteria and Mycoplasmas. Antiviral activity against PRRSV is evaluated using cell-based antiviral assays.
|
| Cell Assay |
In vitro cellular assays for tylosin tartrate involve treating bacterial cultures or virus-infected cells with varying concentrations of the compound. Antibacterial activity is assessed by measuring inhibition of growth. Antiviral activity is assessed by measuring viral replication. Apoptosis induction can be evaluated using Annexin V staining or caspase activity assays.
|
| Animal Protocol |
In vivo animal experiments for tylosin tartrate involve administering the compound to animals (swine, poultry) with bacterial or viral infections. Efficacy is evaluated by measuring clinical improvement, bacterial clearance, or viral load reduction. The compound is used in veterinary medicine for the treatment of respiratory and other infections.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for tylosin tartrate indicate that it is a veterinary antibiotic administered orally or parenterally. Its absorption, distribution, metabolism, and excretion properties are consistent with those of macrolide antibiotics. The compound's pharmacokinetic profile supports its use in veterinary medicine.
|
| Toxicity/Toxicokinetics |
Toxicological data for tylosin tartrate are consistent with those of macrolide antibiotics. The compound should not be used in combination with penicillins. It is intended for veterinary use only and is not for human therapeutic application. Standard safety precautions should be followed.
|
| References |
[1]. Feng-yu Deng, et al. Characterization of the Interaction between Acetylisovaleryltylosin Tartrat and Bovine Serum Albumin without or with Zn2+ and Cu2+ by Spectroscopic Analysis. Guang Pu Xue Yu Guang Pu Fen Xi. 2016 Jul;36(7):2351-7.
[2]. R Okamoto, et al. The activity of 4''-acylated tylosin derivatives against macrolide-resistant gram-positive bacteria. J Antibiot (Tokyo). 1979 May;32(5):542-4. |
| Additional Infomation |
Tylvalosin tartrate (Acetylisovaleryltylosin tartrate) (CAS#: 63428-13-7) has the molecular formula C53H87NO19·x(C4H6O6). The compound is a 16-membered semi-synthetic macrolide antibiotic used in veterinary medicine. It is also known as Acetylisovaleryltylosin tartrate.
|
| Molecular Formula |
C57H93NO25
|
|---|---|
| Molecular Weight |
1192.34
|
| Exact Mass |
1191.603
|
| CAS # |
63428-13-7
|
| Related CAS # |
Tylvalosin;63409-12-1;Tylvalosin-d9
|
| PubChem CID |
56840638
|
| Appearance |
White to light yellow solid powder
|
| LogP |
1.878
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
83
|
| Complexity |
2000
|
| Defined Atom Stereocenter Count |
23
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (83.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8387 mL | 4.1934 mL | 8.3869 mL | |
| 5 mM | 0.1677 mL | 0.8387 mL | 1.6774 mL | |
| 10 mM | 0.0839 mL | 0.4193 mL | 0.8387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
